CliffBio
small molecule

AKYNZEO

NETUPITANT; PALONOSETRON HYDROCHLORIDE

Loss of exclusivitySeptember 2035latest FDA-listed patent expiry
CompanyHELSINN HEALTHCARE SA

Drug detail

Brand nameAKYNZEO
Active ingredientNETUPITANT; PALONOSETRON HYDROCHLORIDE
Strength300MG;EQ 0.5MG BASE
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalOctober 2014
Marketing statusRX

Listed patents

PatentExpiresType
9951016September 2035substance, product
10676440September 2035substance, product
10961195September 2035substance, product
10233154September 2035substance
9271975September 2031use U-2293
10828297December 2030use U-2293
12042494November 2030product
8623826November 2030use U-2293
9186357November 2030use U-2293
11559523November 2030product
9943515November 2030use U-2293
8951969November 2030product

More from HELSINN HEALTHCARE SA

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

AKYNZEO patent cliff — loss of exclusivity September 2035 | CliffBio